CA
NZ
UK
AU
IND
US
● Adjusted diluted earnings were $1.42 per share, while reported earnings fell to 53 cents.
● International medical revenue rose about 17% to roughly 43 million Canadian dollars on German demand.
● Second quarter revenue exceeded $10 billion, up 10%, and full-year guidance was raised.
● Cash was $191.5 million at June 30, with runway management puts through 2028.
● The net loss narrowed by about two-thirds to roughly 15 million Canadian dollars.
● Second quarter revenue rose 48% to about $23 billion on 60% volume growth.
● The trial targets 237 participants, randomized two to one, with a 12-month primary endpoint.
● Pacira sold iovera to Zimmer Biomet, with up to $70 million in milestones possible.
● Consensus is about 73 cents adjusted EPS on revenue near $15.9 billion, per outside estimates.
● Beverage revenue rose about 82% to roughly $101.5 million on the BrewDog acquisition.
Please wait processing your request...